Search - tctmd.com

Displaying 21 - 24 of 24

Sort: Relevancy | Date

ATTRibute-CM Top-Line Results Favorable for Acoramidis in Transthyretin Amyloidosis

News Daily News

ATTRibute-CM Top-Line Results Favorable for Acoramidis

July 17, 2023

ATTR-CM is a serious and underrecognized cause of heart failure. This program will help raise awareness of the signs and symptoms of ATTR-CM, the role of cardiac health professionals in diagnosis, and a treatment option for patients with ATTR-CM

Presentation THT 2023

ATTR-CM is a serious and underrecognized cause of heart failure. This program will help raise awareness of the signs and symptoms of ATTR-CM, the role of cardiac health professionals in diagnosis, and a treatment option for patients with ATTR-CM

Presenter: Charles Dow

March 20, 2023

Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Evaluating clinical findings to support earlier diagnosis and management

Presentation THT 2022

Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Evaluating clinical findings to support earlier diagnosis and management

Presenter: Gregg Lanier

February 01, 2022

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.